NASDAQ:TROV Cardiff Oncology (TROV) Stock Price, News & Analysis → Prepare for a recession unlike any other (From American Hartford Gold Group) (Ad) Free TROV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.06▼$4.4250-Day Range$1.19▼$24.7152-Week Range$0.70▼$3.46Volume702,313 shsAverage Volume648,892 shsMarket Capitalization$45.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Cardiff Oncology alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Cardiff Oncology Stock (NASDAQ:TROV)Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… TROV Stock News HeadlinesFebruary 23, 2024 | benzinga.comCardiff Oncology Stock (NASDAQ:CRDF) Dividends: History, Yield and DatesSeptember 29, 2023 | markets.businessinsider.comCardiff Oncology’s Onvansertib Shows Promise: An Analysis of the Buy Rating RecommendationApril 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. September 26, 2023 | marketwatch.comStocks to Watch: MillerKnoll, Cardiff Oncology, Morphic HoldingsAugust 8, 2023 | marketwatch.comCardiff Oncology Shares Up 26% After Potential Cancer Treatment AdvancesAugust 8, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)May 27, 2023 | fool.comCardiff Oncology (NASDAQ: CRDF)January 13, 2023 | forbes.comCardiff OncologyApril 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. December 14, 2022 | seekingalpha.comCardiff Oncology: Staying The CourseOctober 16, 2022 | markets.businessinsider.comClear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively BuyingSeptember 29, 2022 | finance.yahoo.comCardiff Oncology, Inc. (CRDF)September 24, 2022 | seekingalpha.comCRDF Cardiff Oncology, Inc.August 25, 2022 | msn.comLooking Into Cardiff Oncology's Return On Capital EmployedAugust 22, 2022 | seekingalpha.comCardiff Oncology: Down But Not OutJuly 28, 2022 | finance.yahoo.comCardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?May 31, 2022 | stocknews.com5 Oncology Stocks Wall Street Predicts Will Rally 135% or MoreMarch 22, 2022 | prnewswire.comCardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLCAugust 5, 2021 | prnewswire.comCardiff Oncology Reports Second Quarter 2021 Results and Provides Business UpdatesSee More Headlines Receive TROV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TROV CUSIPN/A CIK1213037 Webwww.trovagene.com Phone(858) 952-7570FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,410,000.00 Net Margins-3,688.31% Pretax MarginN/A Return on Equity-202.00% Return on Assets-122.92% Debt Debt-to-Equity Ratio0.12 Current Ratio2.37 Quick Ratio2.37 Sales & Book Value Annual Sales$250,000.00 Price / Sales183.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book4.44Miscellaneous Outstanding Shares11,011,000Free FloatN/AMarket Cap$45.92 million OptionableNot Optionable Beta1.04 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMark ErlanderChief Executive Officer & DirectorVicki KelemenChief Operating Officer & Executive Vice PresidentBrigitte LindsaySecretary & Vice President-FinanceKey CompetitorsQuince TherapeuticsNASDAQ:QNCXCidara TherapeuticsNASDAQ:CDTXDyadic InternationalNASDAQ:DYAINKGen BiotechNYSE:NKGNAVROBIONASDAQ:AVROView All Competitors TROV Stock Analysis - Frequently Asked Questions How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:TROV) announced its earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%. When did Cardiff Oncology's stock split? Cardiff Oncology's stock reverse split on the morning of Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Idera Pharmaceuticals (IDRA). This page (NASDAQ:TROV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
